NTGN Neon Therapeutics Inc.

1.88
-0.18  -9%
Previous Close 2.06
Open 2.08
Price To Book 0.86
Market Cap 53,356,457
Shares 28,381,094
Volume 195,621
Short Ratio
Av. Daily Volume 675,352
Stock charts supplied by TradingView

NewsSee all news

  1. Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (NASDAQ:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the

  2. Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

    Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods Proprietary capabilities to be integrated into Neon's RECON® bioinformatics

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b data due 3Q 2020.
NEO-PV-01 + Keytruda - NT-002
Non-small Cell Lung Cancer (NSCLC)
Phase 1b data released at SITC November 8, 2019.
NEO-PV-01 + nivolumab NT-001
Melanoma, Lung Cancer or Bladder Cancer
Phase 1b data due 2H 2020.
NEO-PV-01 and nivolumab - NT-003
Melanoma

Latest News

  1. Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (NASDAQ:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the

  2. Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

    Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods Proprietary capabilities to be integrated into Neon's RECON® bioinformatics